Entera Bio Ownership
| ENTX Stock | USD 1.64 0.06 3.53% |
Shares in Circulation | First Issued 2016-06-30 | Previous Quarter 37.1 M | Current Value 37.6 M | Avarage Shares Outstanding 20.4 M | Quarterly Volatility 9.2 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Entera |
Entera Stock Ownership Analysis
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.26. Entera Bio had not issued any dividends in recent years. Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel. Entera Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 22 people. To learn more about Entera Bio call Miranda MBA at 972 2 532 7151 or check out https://www.enterabio.com.Besides selling stocks to institutional investors, Entera Bio also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Entera Bio's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Entera Bio's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Entera Bio Quarterly Liabilities And Stockholders Equity |
|
About 19.0% of Entera Bio are currently held by insiders. Unlike Entera Bio's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Entera Bio's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Entera Bio's insider trades
Entera Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Entera Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Entera Bio backward and forwards among themselves. Entera Bio's institutional investor refers to the entity that pools money to purchase Entera Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Hightower Advisors, Llc | 2024-03-31 | 0.0 | Two Sigma Securities, Llc | 2024-03-31 | 0.0 |
Entera Bio Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Entera Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Entera Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Entera Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Entera Stock Analysis
When running Entera Bio's price analysis, check to measure Entera Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entera Bio is operating at the current time. Most of Entera Bio's value examination focuses on studying past and present price action to predict the probability of Entera Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entera Bio's price. Additionally, you may evaluate how the addition of Entera Bio to your portfolios can decrease your overall portfolio volatility.